Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts

Treatment with cisplatin-containing chemotherapy regimens causes hearing loss in 40–60% of cancer patients. It has been suggested that genetic variants in the genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can predict the development of cisplatin-induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagleitner, Melanie M., Coenen, Marieke J. H., Patino-Garcia, Ana, de Bont, Eveline S. J. M., Gonzalez-Neira, Anna, Vos, Hanneke I., van Leeuwen, Frank N., Gelderblom, Hans, Hoogerbrugge, Peter M., Guchelaar, Henk-Jan, te Loo, Maroeska W. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281251/
https://www.ncbi.nlm.nih.gov/pubmed/25551397
http://dx.doi.org/10.1371/journal.pone.0115869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281251/
https://www.ncbi.nlm.nih.gov/pubmed/25551397
http://dx.doi.org/10.1371/journal.pone.0115869

Ejemplares similares